vs
艾伯维（ABBV）与泰尼特医疗（HCSG）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是泰尼特医疗的35.6倍（$16.6B vs $466.7M）。艾伯维同比增速更快（10.0% vs 6.6%）。艾伯维自由现金流更多（$4.9B vs $16.0M）。过去两年艾伯维的营收复合增速更高（16.2% vs 5.0%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
泰尼特医疗集团是一家总部位于达拉斯的美国上市营利性跨国医疗服务企业，旗下通过品牌、子公司、合资企业及合作项目（包括联合外科合作伙伴国际USPI），运营着65家医院与超450家医疗机构，此外还经营康尼弗医疗解决方案，为医疗系统及其他客户提供医疗配套服务支持。
ABBV vs HCSG — 直观对比
营收规模更大
ABBV
是对方的35.6倍
$466.7M
营收增速更快
ABBV
高出3.4%
6.6%
自由现金流更多
ABBV
多$4.9B
$16.0M
两年增速更快
ABBV
近两年复合增速
5.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $466.7M |
| 净利润 | $1.8B | — |
| 毛利率 | 72.6% | 15.4% |
| 营业利润率 | 27.3% | 6.1% |
| 净利率 | 10.9% | — |
| 营收同比 | 10.0% | 6.6% |
| 净利润同比 | 8354.5% | — |
| 每股收益（稀释后） | $1.02 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVHCSG
| Q4 25 | $16.6B | $466.7M | ||
| Q3 25 | $15.8B | $464.3M | ||
| Q2 25 | $15.4B | $458.5M | ||
| Q1 25 | $13.3B | $447.7M | ||
| Q4 24 | $15.1B | $437.8M | ||
| Q3 24 | $14.5B | $428.1M | ||
| Q2 24 | $14.5B | $426.3M | ||
| Q1 24 | $12.3B | $423.4M |
净利润ABBVHCSG
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | $43.0M | ||
| Q2 25 | $938.0M | $-32.4M | ||
| Q1 25 | $1.3B | $17.2M | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | $14.0M | ||
| Q2 24 | $1.4B | $-1.8M | ||
| Q1 24 | $1.4B | $15.3M |
毛利率ABBVHCSG
| Q4 25 | 72.6% | 15.4% | ||
| Q3 25 | 66.4% | 20.8% | ||
| Q2 25 | 71.8% | 0.6% | ||
| Q1 25 | 70.0% | 15.2% | ||
| Q4 24 | 70.9% | 13.4% | ||
| Q3 24 | 70.9% | 14.8% | ||
| Q2 24 | 70.9% | 9.7% | ||
| Q1 24 | 66.7% | 15.2% |
营业利润率ABBVHCSG
| Q4 25 | 27.3% | 6.1% | ||
| Q3 25 | 12.1% | 12.3% | ||
| Q2 25 | 31.7% | -9.1% | ||
| Q1 25 | 28.0% | 5.3% | ||
| Q4 24 | -9.9% | 3.4% | ||
| Q3 24 | 26.5% | 4.4% | ||
| Q2 24 | 27.6% | -0.5% | ||
| Q1 24 | 22.7% | 5.0% |
净利率ABBVHCSG
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | 9.3% | ||
| Q2 25 | 6.1% | -7.1% | ||
| Q1 25 | 9.6% | 3.8% | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | 3.3% | ||
| Q2 24 | 9.5% | -0.4% | ||
| Q1 24 | 11.1% | 3.6% |
每股收益（稀释后）ABBVHCSG
| Q4 25 | $1.02 | $0.43 | ||
| Q3 25 | $0.10 | $0.59 | ||
| Q2 25 | $0.52 | $-0.44 | ||
| Q1 25 | $0.72 | $0.23 | ||
| Q4 24 | $-0.03 | $0.15 | ||
| Q3 24 | $0.88 | $0.19 | ||
| Q2 24 | $0.77 | $-0.02 | ||
| Q1 24 | $0.77 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $168.0M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $510.2M |
| 总资产 | $134.0B | $794.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVHCSG
| Q4 25 | $5.3B | $168.0M | ||
| Q3 25 | $5.7B | $177.5M | ||
| Q2 25 | $6.5B | $134.5M | ||
| Q1 25 | $5.2B | $114.8M | ||
| Q4 24 | $5.6B | $107.3M | ||
| Q3 24 | $7.3B | $103.8M | ||
| Q2 24 | $13.2B | $105.6M | ||
| Q1 24 | $18.1B | $104.9M |
总债务ABBVHCSG
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVHCSG
| Q4 25 | $-3.3B | $510.2M | ||
| Q3 25 | $-2.6B | $496.0M | ||
| Q2 25 | $-183.0M | $477.0M | ||
| Q1 25 | $1.4B | $514.2M | ||
| Q4 24 | $3.3B | $499.9M | ||
| Q3 24 | $6.0B | $488.7M | ||
| Q2 24 | $6.8B | $471.4M | ||
| Q1 24 | $8.0B | $474.6M |
总资产ABBVHCSG
| Q4 25 | $134.0B | $794.3M | ||
| Q3 25 | $133.9B | $804.3M | ||
| Q2 25 | $137.2B | $802.2M | ||
| Q1 25 | $136.2B | $823.0M | ||
| Q4 24 | $135.2B | $802.8M | ||
| Q3 24 | $143.4B | $805.8M | ||
| Q2 24 | $141.9B | $799.7M | ||
| Q1 24 | $148.9B | $803.9M |
负债/权益比ABBVHCSG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $17.4M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $16.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 3.4% |
| 资本支出强度资本支出/营收 | 2.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $139.2M |
8季度趋势，按日历期对齐
经营现金流ABBVHCSG
| Q4 25 | $5.2B | $17.4M | ||
| Q3 25 | $7.0B | $71.3M | ||
| Q2 25 | $5.2B | $28.8M | ||
| Q1 25 | $1.6B | $27.5M | ||
| Q4 24 | $7.0B | $36.2M | ||
| Q3 24 | $5.4B | $4.3M | ||
| Q2 24 | $2.3B | $16.3M | ||
| Q1 24 | $4.0B | $-26.0M |
自由现金流ABBVHCSG
| Q4 25 | $4.9B | $16.0M | ||
| Q3 25 | $6.6B | $70.0M | ||
| Q2 25 | $4.9B | $27.4M | ||
| Q1 25 | $1.4B | $25.8M | ||
| Q4 24 | $6.8B | $34.8M | ||
| Q3 24 | $5.2B | $2.9M | ||
| Q2 24 | $2.0B | $15.0M | ||
| Q1 24 | $3.8B | $-28.2M |
自由现金流率ABBVHCSG
| Q4 25 | 29.4% | 3.4% | ||
| Q3 25 | 42.1% | 15.1% | ||
| Q2 25 | 31.7% | 6.0% | ||
| Q1 25 | 10.5% | 5.8% | ||
| Q4 24 | 44.7% | 7.9% | ||
| Q3 24 | 35.9% | 0.7% | ||
| Q2 24 | 14.0% | 3.5% | ||
| Q1 24 | 31.3% | -6.7% |
资本支出强度ABBVHCSG
| Q4 25 | 2.0% | 0.3% | ||
| Q3 25 | 2.4% | 0.3% | ||
| Q2 25 | 1.7% | 0.3% | ||
| Q1 25 | 1.8% | 0.4% | ||
| Q4 24 | 1.9% | 0.3% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 1.7% | 0.3% | ||
| Q1 24 | 1.6% | 0.5% |
现金转化率ABBVHCSG
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 1.66× | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | 1.60× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | 0.31× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | -1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
